Vical Inc. (VICL) said that the company and Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK) finalized the general design of a pivotal, multinational Phase 3 trial of TransVax, the companies' therapeutic cytomegalovirus, or CMV, vaccine for transplant recipients. This progress triggers a $10 million milestone payment to Vical.
Based on guidance from the U.S. Food and Drug Administration and the European Medicines Agency, the companies have confirmed that CMV disease will not be the primary endpoint in the Phase 3 trial.
The companies expect to begin the Phase 3 trial of TransVax for hematopoietic stem cell transplant recipients in the second half of 2012, and initiate a Phase 2 efficacy trial of TransVax for solid organ transplant recipients shortly thereafter. Specific endpoints and trial design concepts will be announced when the trials begin, Vical added.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.